Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis.
- Aeberli D Department of Rheumatology, Immunology and Allergology , University Hospital of Bern , Bern , Switzerland.
- Kamgang R Department of Rheumatology, Immunology and Allergology , University Hospital of Bern , Bern , Switzerland.
- Balani D Department of Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland; Group for Bone Biology & Orthopaedic Research, Department of Clinical Research, University of Bern, Bern, Switzerland.
- Hofstetter W Group for Bone Biology & Orthopaedic Research, Department of Clinical Research , University of Bern , Bern , Switzerland.
- Villiger PM Department of Rheumatology, Immunology and Allergology , University Hospital of Bern , Bern , Switzerland.
- Seitz M Department of Rheumatology, Immunology and Allergology , University Hospital of Bern , Bern , Switzerland.
- 2016-01-29
Published in:
- RMD open. - 2016
English
OBJECTIVE
To investigate the regulatory effect of tumour necrosis factor (TNF) blockade with infliximab on the distribution of peripheral blood monocyte subpopulations in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
METHODS
Purified CD11b+CD14+ monocytes from 5 patients with RA and 5 AS were analysed ex vivo before and after infliximab treatment by flow cytometry for CD16, CD163, CD11b, C-C chemokine receptor type 2 (CCR2) and CXC chemokine receptor 4 (CXCR4) at baseline and at days 2, 14, 84 and 168 after the first infliximab administration. Serum levels of the stromal cell-derived factor (SDF)-1 and monocyte chemotactic peptide (MCP)-1 at different time points were measured in either patient group before and on infliximab treatment.
RESULTS
Anti-TNF treatment with infliximab led to a significant increase of circulating CD11b+ non-classical and a concomitantly decrease of CD11b+ classical monocytes, to a decline in SDF-1 levels and reduced expression of CCR2 and CXCR4 on non-classical monocyte subpopulation.
CONCLUSIONS
Our study shows, that TNFα blockade by infliximab resulted in a dichotomy of the regulation of classical and non-classical monocytes that might have substantial impact on inhibition of osteoclastogenesis and of subsequent juxta-articular bone destruction and systemic bone loss in RA and AS.
To investigate the regulatory effect of tumour necrosis factor (TNF) blockade with infliximab on the distribution of peripheral blood monocyte subpopulations in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
METHODS
Purified CD11b+CD14+ monocytes from 5 patients with RA and 5 AS were analysed ex vivo before and after infliximab treatment by flow cytometry for CD16, CD163, CD11b, C-C chemokine receptor type 2 (CCR2) and CXC chemokine receptor 4 (CXCR4) at baseline and at days 2, 14, 84 and 168 after the first infliximab administration. Serum levels of the stromal cell-derived factor (SDF)-1 and monocyte chemotactic peptide (MCP)-1 at different time points were measured in either patient group before and on infliximab treatment.
RESULTS
Anti-TNF treatment with infliximab led to a significant increase of circulating CD11b+ non-classical and a concomitantly decrease of CD11b+ classical monocytes, to a decline in SDF-1 levels and reduced expression of CCR2 and CXCR4 on non-classical monocyte subpopulation.
CONCLUSIONS
Our study shows, that TNFα blockade by infliximab resulted in a dichotomy of the regulation of classical and non-classical monocytes that might have substantial impact on inhibition of osteoclastogenesis and of subsequent juxta-articular bone destruction and systemic bone loss in RA and AS.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1136/rmdopen-2015-000079
- PMID 26819749
- Persistent URL
- https://sonar.ch/global/documents/58267
Statistics
Document views: 40
File downloads:
- Full-text: 0